Largest biotech by total assets
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total assets, at SEK 920.3B, ahead of Gilead Sciences (SEK 599.6B) and Biogen (SEK 299.1B). Figures as of 18 Nov 2026, 14:43 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSEK 920.3B
- Median
- SEK 26B
- Combined market value
- SEK 8.61T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SEK 920.3B | SEK 2.49T | SEK 4,600.78 | 1.10% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | SEK 599.6B | SEK 2.14T | SEK 1,723.77 | 0.34% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | SEK 299.1B | SEK 378.2B | SEK 2,558.22 | 0.41% up | 49% up | ||
| 4 | BioNTechBNTX · Health Care | SEK 247.8B | SEK 214.4B | SEK 864.68 | 0.30% up | 16% down | ||
| 5 | ModernaMRNA · Health Care | SEK 125.3B | SEK 852.6B | SEK 2,107.17 | 0.30% up | 755% up | ||
| 6 | argenxARGX · Health Care | SEK 88.2B | SEK 613.4B | SEK 9,754.50 | 1.34% up | 4% up | ||
| 7 | QiagenQGEN · Health Care | SEK 63.8B | SEK 104.3B | SEK 505.10 | 0.06% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | SEK 47.1B | SEK 170.3B | SEK 1,682.32 | 0.19% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | SEK 30.5B | SEK 95.2B | SEK 601.66 | 0.29% down | 22% up | ||
| 10 | RepligenRGEN · Health Care | SEK 30B | SEK 110.5B | SEK 1,727.88 | 4.87% up | 5% up | ||
| 11 | ExelixisEXEL · Health Care | SEK 28.9B | SEK 170B | SEK 696.65 | 0.11% up | 63% up | ||
| 12 | Bio-TechneTECH · Health Care | SEK 26.3B | SEK 116.1B | SEK 738.81 | 0.13% up | 26% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | SEK 25.7B | SEK 111.4B | SEK 977.54 | 0.27% up | 37% up | ||
| 14 | Revolution MedicinesRVMD · Health Care | SEK 23.9B | SEK 354.8B | SEK 1,640.51 | 0.74% down | 131% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | SEK 23B | SEK 41.4B | SEK 426.65 | 4.60% up | 21% down | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | SEK 17.7B | SEK 106.5B | SEK 1,247.21 | 1.03% up | 87% up | ||
| 17 | Krystal BiotechKRYS · Health Care | SEK 13.5B | SEK 91.1B | SEK 3,072.57 | 1.31% up | 46% up | ||
| 18 | ImmunovantIMVT · Health Care | SEK 9.7B | SEK 70.5B | SEK 340.53 | 0.93% up | 43% up | ||
| 19 | CG OncologyCGON · Health Care | SEK 8B | SEK 72B | SEK 806.42 | 0.56% up | 85% up | ||
| 20 | Twist BioscienceTWST · Health Care | SEK 6.5B | SEK 78.5B | SEK 1,151.21 | 1.18% up | 340% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | SEK 5.2B | SEK 47.3B | SEK 292.17 | 0.95% up | 88% up | ||
| 22 | ImmunityBioIBRX · Health Care | SEK 5.1B | SEK 67.2B | SEK 63.19 | 0.64% down | 193% up | ||
| 23 | Scholar Rock HoldingSRRK · Health Care | SEK 4.1B | SEK 57.8B | SEK 473.51 | 3.39% up | 14% up | ||
| 24 | Kodiak SciencesKOD · Health Care | SEK 3.6B | SEK 64.1B | SEK 979.52 | 0.39% down | 396% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 10.1589 SEK).
Questions and answers
Which biotech rank first by total assets?
Amgen (SEK 920.3B), Gilead Sciences (SEK 599.6B) and Biogen (SEK 299.1B) are the top three of the 24 biotech ranked by total assets as of 18 Nov 2026, 14:43 UTC.
How many biotech are in this ranking?
24 are ranked by total assets.
What are these biotech worth together?
The 24 biotech ranked by total assets have a combined market value of SEK 8.61T as of 18 Nov 2026, 14:43 UTC.
What does ranking by total assets measure?
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-assets
Underlying data: Yahoo Finance; SEC EDGAR.